Phase I pharmacology study of oral and intravenous BCX-1777 [forodesine] in patients with refractory T-cell and non-T-cell malignancies

Trial Profile

Phase I pharmacology study of oral and intravenous BCX-1777 [forodesine] in patients with refractory T-cell and non-T-cell malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2013

At a glance

  • Drugs Forodesine (Primary)
  • Indications Astrocytoma; Biliary cancer; Colorectal cancer; Gastric cancer; Haematological malignancies; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2008 Status changed from in progres to completed.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top